A practical reference on GLP-1 receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-17 and is reviewed periodically as new material appears.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
| Property | Value | Notes |
|---|---|---|
| Molecular formula (free base) | C187H291N45O59 | Approximate; salt and hydrate forms differ |
| Molecular weight | ~4113.6 Da | Varies with counterion and hydration |
| Appearance | White to off-white powder | Lyophilized research material |
| Solubility class | Freely soluble in water | As formulated; native peptide less stable near neutral pH |
| Typical storage | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
=== Scraped surface generators === The world’s first patent for a slurry ice generator was filed by Sunwell Technologies Inc. of Canada in 1976. Sunwell Technologies Inc. introduced slurry ice under the trade name deepchill ice, in the late 1970s. Slurry ice is created through a process of forming spherical ice crystals within a liquid. The slurry ice generator is a scraped-surface vertical shell and tube heat exchanger. It consists of concentric tubes with refrigerant flowing between them and the water/freezing point depressant solution in the inner tube. The inner surface of the inner tube is wiped using a mechanism which in the original Sunwell design consists of a central shaft, spring-loaded plastic blades, bearings, and seals. The small ice crystals formed in the solution near the tube surface are wiped away from the surface and mixed with unfrozen water, forming the slurry. Other slurry ice generators adapted the first idea of wiping the surface using an auger originally designed to create flake ice. Wipers also can be brushes or fluidized bed heat exchangers for ice crystallization. In these heat exchangers, steel particles circulate with the fluid, mechanically removing the crystals from the surface. At the outlet, steel particles and slurry ice are separated.
As of 2008, no açaí products have been evaluated by the FDA, and their efficacy is doubtful. As of 2009, there is no scientific evidence that açaí consumption affects body weight, promotes weight loss or has any positive health effect.
=== Drugs that induce a type 1 diabetes like syndrome === Some medicines can reduce insulin production or damage β cells, resulting in a disease that resembles type 1 diabetes. The antiviral drug didanosine triggers pancreas inflammation in 5 to 10% of those who take it, sometimes causing lasting β-cell damage. Similarly, up to 5% of those who take the anti-protozoal drug pentamidine experience β-cell destruction and diabetes. Several other drugs cause diabetes by reversibly reducing insulin secretion, namely statins (which may also damage β cells), the post-transplant immunosuppressants cyclosporin A and tacrolimus, the leukemia drug L-asparaginase, and the antibiotic gatifloxicin.
Secondary burial is a burial, cremation, or inhumation that is dug into a pre-existing barrow or grave any time after its initial construction. It is often associated with the belief that there is a liminal phase between the time that a person dies and finally decays.
Sources: en.wikipedia.org
=== Development === On July 23, 2020, the series was renewed for a third season at the aftershow hosted by Aisha Tyler for the 2020 San Diego Comic-Con@Home, less than two months before the second-season premiere. Showrunner Eric Kripke revealed that he was already working with the scripts for the season in October, hoping to have them finished and start production in early 2021 as long as the condition of the COVID-19 pandemic improved. Due to the restrictions of live-action productions during the pandemic, Kripke and the producers have the idea of keeping the fans of the series engaged while they waited for the release of the third season, leading to the anthology animated spin-off miniseries The Boys Presents: Diabolical. In January 2022, it was confirmed that the season would be getting eight episodes and that would be also following the same weekly release similarly to the previous season, with three episodes released on the premiere date and the rest being released on a weekly basis.
Insect flour: Pulverized, freeze-dried insects (e.g., cricket flour). Insect burger: Hamburger patties made from insect powder / insect flour (mainly from mealworms or from house cricket) and other ingredients. Insect fitness bars: Protein bars containing insect powder (mostly house crickets). Insect pasta: Pasta made of wheat flour, fortified with insect flour (house crickets or mealworms). Insect bread (Finnish Sirkkaleipä): Bread baked with insect flour (mostly house crickets). Insect snacks: Crisps, flips or small snacks (bites) made with insect powder and other ingredients. Food and drink companies such as the Australian brewery Bentspoke Brewing Co, Canadian Crickstart Food, and the South African startup Gourmet Grubb have introduced insect-based beer, protein bars, a milk alternative, and insect ice cream. While these products are more and more available, recent research suggests that insect-based foods are unlikely to significantly replace traditional meat. Only a small minority of consumers would consider replacing meat with insects, which are generally viewed as a complement rather than a substitute. In the US and Europe, where insects are not traditionally eaten, cultural barriers limit adoption, making plant-based alternatives a far more promising solution.
B-DNA The "standard" or classical structural conformation of the DNA double helix in vivo, thought to represent an average of the various distinct conformations assumed by very long DNA molecules under physiological conditions. The B-form double helix has a right-handed twist with a diameter of 23.7 ångströms and a pitch of 35.7 ångströms or about 10.5 base pairs per full turn, such that each nucleotide pair is rotated 36° around the helical axis with respect to its neighboring pairs. See also A-DNA and Z-DNA.
Sources: en.wikipedia.org
== Structure and spectroscopy == The C−N=C=N−C core of carbodiimides (N=C=N) is linear, being related to the structure of allene. The molecule has idealized C2 symmetry. The N=C=N moiety gives characteristic IR spectroscopic signature at 2117 cm−1. The 15N NMR spectrum shows a characteristic shift of 275 ppm upfield of nitric acid and the 13C NMR spectrum features a peak at about 139 ppm downfield from TMS.
Grade I: Mild ptosis—The nipple is at the level of the infra-mammary fold and above most of the lower breast tissue. Grade II: Moderate ptosis—The nipple is located below the infra-mammary fold but higher than most of the breast tissue hangs. Grade III: Advanced ptosis—The nipple is below the inframammary fold and at the level of maximum breast projection. Pseudoptosis—The nipple is located either at or above the infra-mammary fold, while the lower half of the breast sags below the fold. This is most often seen when a woman stops nursing, as her milk glands atrophy, causing her breast tissue to sag. Parenchymal Maldistribution—The lower breast tissue is lacking fullness, the inframammary fold is very high, and the nipple and areola are relatively close to the fold. This is usually a developmental deformity.
The enzyme, found in bacteria, interacts with an extracytoplasmic substrate binding protein and mediates the import of nitrate, nitrite, and cyanate. ATP + H2O + nitrate [nitrate - binding protein][side 1] = ADP + phosphate + nitrate [side 2] + [nitrate - binding protein][side 1] 7.3.2.5 ABC-type molybdate transporter The expected taxonomic range for this enzyme is: Archaea, Eukaryota, Bacteria. The enzyme, found in bacteria, interacts with an extracytoplasmic substrate binding protein and mediates the high-affinity import of molybdate and tungstate. Does not undergo phosphorylation during the transport process. ATP + H2O + molybdate [molybdate - binding protein][side 1] = ADP + phosphate + molybdate [side 2] + [molybdate - binding protein][side 1] 7.3.2.6 ABC-type tungstate transporter The expected taxonomic range for this enzyme is: Archaea, Bacteria. The enzyme, characterized from the archaeon Pyrococcus furiosus, the Gram-positive bacterium Peptoclostridium acidaminophilum (Eubacterium acidaminophilum) and the Gram-negative bacterium Campylobacter jejuni, interacts with an extracytoplasmic substrate binding protein and mediates the import of tungstate into the cell for incorporation into tungsten-dependent enzymes. ATP + H2O + tungstate [tungstate - binding protein][side 1] = ADP + phosphate + tungstate [side 2] + [tungstate - binding protein][side 1]
The Germans pulled their remaining forces out of Calabria to send them to Salerno. Under the Allied occupation, some fascists waged a terrorist struggle on behalf of the Salo republic, although they tended to be concerned about social reforms that might weaken their power while a minority such as Prince Valerio Pignatelli were ideological Fascists. In June 1944, celebrations in Reggio Calabria over the liberation of Rome were disturbed by Fascists.
Sources: en.wikipedia.org
It is a modified version of the natural hormone, with three amino acid changes and a fatty acid side chain added. These edits extend its half-life from minutes to about one week. The core receptor activity is retained.
Both deliver the same active peptide and act on the same receptor. The tablet includes an absorption enhancer because peptides are poorly taken up intact from the gut. Bioavailability of the oral route is substantially lower, so the two are not dose-equivalent.
No, it is entirely synthetic and does not occur in nature. Native GLP-1 is produced in the gut and pancreas, but the analog is manufactured by chemical synthesis or recombinant methods. Traces of the analog are not expected in people who never received it.
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.